27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks are in the midst of an "epic" selloff, Evercore ISI Mark Schoenebaum told CNBC on Monday.
Schoenebaum is known for his coverage of big pharma, including Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Inc (NASDAQ: BIIB), Pfizer (NYSE: PFE) and AbbVie Inc (NYSE: ABBV).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"What's happened fundamentally? Most people attribute the beginning of the selloff to Hillary Clinton's tweet back in October about drug pricing. That has just cast a shadow over the whole group that this set of companies just no longer has pricing power," the analyst said.
While the exact merits of this logic can be debated, Schoenebaum said the threat of regulation has caused groups of investors to avoid biotech until the Presidential elections are over.
He said that while sector Price-to-Earnings ratios are near bottom -- "typically a buying signal" -- there's a caveat. Biotechs have traded at these levels longer than Schoenebaum's seen in the past, giving credence to the possibility that prices remain depressed.
"Finally, we've had some product disappointments out of smaller companies," he explained. Past innovation and product developments drove the biotech bull market, and a lack of such could be another headwind facing investors.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
5 Catalysts That Could Be Coming
Rather than buying a basket of biotechs, Schoenebaum said it might make more sense to pick individual names that could have catalysts coming in 2016.
Amgen, Inc. (NASDAQ: AMGN) is one name he mentioned. The company will have data for "very important" cholesterol lowering medication by mid-2016. "I expect that to be favorable data and should drive the stock at least modestly higher.
Biogen, meanwhile, is also expecting data later this year. If the drug anti-LINGO "were to work, it would absolutely transform the earnings trajectory of this stock," the analyst added. Biogen has about $20 per share downside based on this data, but $100 upside.
Celgene Corporation (NASDAQ: CELG)'s Revlimid data coming out mid-year, which "if successful...will push numbers a little bit higher," Schoenebaum said.
Gilead's Hep B development is a "long shot," and Wall Street doesn't expect it to work. However if the data were positive, "it would transform the company, and you're paying a single-digit P/E for that stock right now."
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has "lots of new drug [data]" coming out in the next three months -- "most of these will be positivie, and is likely to drive that stock higher." Schoenebaum said BioMarin's reward could outweigh the risk by three or four to one.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is down a little over 3 percent on Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.